HempTalk - Business Blogs and Press Releases
Project CBD Newsletter: CBD and Alzheimer’s Brain Inflammation, Psilocybin Research, Cannabis for Pain, and Drug Policy Analysis
This week’s newsletter covers CBD’s potential to reduce Alzheimer’s-related brain inflammation, psilocybin’s promise for pain relief and neurological conditions, cannabis as an alternative to opioids for chronic pain, and critical perspectives on AI safety and U.S. drug policy.
Noteworthy Read
CBD Shows Early Promise for Reducing Brain Inflammation in Alzheimer’s Model (Discover Magazine)
New research in a mouse model of Alzheimer’s disease suggests CBD may reduce chemical markers associated with brain inflammation. The findings add to growing interest in cannabinoids and neuroinflammation, and highlight the importance of further research to explore efficacy in humans.
Read the full article
View more in CBD
More Noteworthy Reading
Parents Sue OpenAI After Their Son Dies of a Drug Overdose (CBS News)
CBS News reports on a lawsuit filed by the parents of a 19-year-old who died of a drug overdose after allegedly using ChatGPT to seek drug-related advice. The case raises broader questions about AI safety, health misinformation, platform accountability, and how emerging technologies should handle conversations involving substance use and medical risk.
Read more
View more in Drug Interactions
Trump’s ‘Narco-Terrorism’ War in Latin America Is More About Fighting Leftists Than Drug Runners (The Conversation)
This analysis argues that the Trump administration’s framing of Latin American drug cartels as “narco-terrorist” threats echoes earlier U.S. interventions that blurred drug policy, national security, and anti-leftist foreign policy goals. Considering drug-war rhetoric within a longer history of militarized U.S. policy in the region, it raises questions about whether anti-drug campaigns are again being used to justify broader geopolitical aims.
Medical Cannabis Helps People With Hypermobility Disorders Experience Less Pain, Consume Fewer Opioids (NORML)
A new study found that patients with hypermobility-related disorders reported reduced pain and lower opioid use after beginning medical cannabis treatment. The results support further investigation of cannabis-based therapies for complex chronic pain conditions, especially where conventional medications provide incomplete relief or carry significant side effects.
Research Round-Up
Case Report: High-Dose Psilocybin-Containing Mushroom Improves Advanced Alzheimer’s Disease (Frontiers in Neuroscience)
A case report describes temporary functional improvements in an older woman with advanced Alzheimer’s disease after supervised administration of high-dose psilocybin-containing mushrooms. The report is striking though limited: it involves a single patient and does not show disease reversal, but it makes for a strong argument in support of future controlled research.
Read more
View more in Psychedelics
Magic Mushroom Compound Enhances Nerve Pain Medication (PsyPost)
New mouse research suggests psilocybin may provide lasting relief from neuropathic pain and enhance the effects of gabapentin, a commonly prescribed nerve pain medication. The findings point to a possible future role for psychedelics in chronic pain research, but the work remains preclinical and does not establish that psilocybin-gabapentin combinations are safe or effective in humans.
